Fyarro

FYARRO™ (nab-sirolimus) is an mTOR inhibitor formulated as sirolimus protein-bound particles (albumin-bound) for IV infusion. FDA Indication: Treatment of adults with locally advanced unresectable or metastatic malignant PEComa. (Approved November 2021). Mechanism: Inhibits the mTOR pathway, a key driver of PEComa progression. Clinical Data: The AMPECT Phase 2 trial showed an objective response rate of ~39%, with durable responses in patients with advanced malignant PEComa.